FDA approves first RSV vaccine for at-risk adults in their 50s
What is the minimum age for which the FDA has recently approved GSK's RSV vaccine?
The FDA has recently approved GSK's RSV vaccine for use in adults aged 50 and older who are at increased risk of severe RSV. This makes it the first RSV vaccine approved for this age group. Previously, the vaccine was only approved for adults aged 60 and older.
Which other companies are developing RSV vaccines for adults, and what age groups are these vaccines being tested on?
Two other companies, Pfizer and Moderna, are also developing RSV vaccines for adults. Pfizer's vaccine is approved for adults 60 years and older, and the company is testing its shot in younger adults. Moderna is also testing its RSV vaccine in younger adults.
What are the plans for further trials of the GSK RSV vaccine, and what age group will these trials focus on?
GSK has plans for further trials of its RSV vaccine, focusing on adults between 18 and 49 years old. The company expects the results of these trials in the second half of this year. Additionally, GSK plans to present more trial results in June, looking at boosters spaced out as much as three years after an initial shot.